R Maj

Summary

Affiliation: Pharmacia and Upjohn
Country: USA

Publications

  1. ncbi request reprint PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat
    R Maj
    CNS Preclinical Research, Pharmacia and Upjohn SpA, Nerviano, MI, Italy
    Eur J Pharmacol 359:27-32. 1998
  2. ncbi request reprint Synthesis and preliminary biological evaluation of new alpha-amino amide anticonvulsants incorporating a dextromethorphan moiety
    P Pevarello
    Pharmacia and Upjohn, Chem Dept, Nerviano, Milan, Italy
    Bioorg Med Chem Lett 9:1783-8. 1999
  3. ncbi request reprint Safinamide: from molecular targets to a new anti-Parkinson drug
    C Caccia
    Newron Pharmaceuticals SpA, Bresso, MI, Italy
    Neurology 67:S18-23. 2006
  4. ncbi request reprint Receptor adaptive responsiveness in disease models: 6-OHDA lesioned and spontaneously hypertensive rats
    C Caccia
    Research and Development, CNS Line, Farmitalia Carlo Erba, Nerviano, Italy
    J Recept Res 8:97-105. 1988

Detail Information

Publications4

  1. ncbi request reprint PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat
    R Maj
    CNS Preclinical Research, Pharmacia and Upjohn SpA, Nerviano, MI, Italy
    Eur J Pharmacol 359:27-32. 1998
    ..Glutamate release inhibition may play a major role in neuroprotection, but an additional mechanism(s) of action might be relevant for the anticonvulsant activity of PNU-151774E in this model...
  2. ncbi request reprint Synthesis and preliminary biological evaluation of new alpha-amino amide anticonvulsants incorporating a dextromethorphan moiety
    P Pevarello
    Pharmacia and Upjohn, Chem Dept, Nerviano, Milan, Italy
    Bioorg Med Chem Lett 9:1783-8. 1999
    ..Here we describe the enantioselective and enantiospecific syntheses and the initial in vitro and in vivo biological evaluation of new hybrid structures between 1 and a previously disclosed alpha-amino amide anticonvulsant (3)...
  3. ncbi request reprint Safinamide: from molecular targets to a new anti-Parkinson drug
    C Caccia
    Newron Pharmaceuticals SpA, Bresso, MI, Italy
    Neurology 67:S18-23. 2006
    ..Therefore, safinamide may be used in PD to reduce l-dopa dosage and also represents a valuable therapeutic drug to test disease-modifying potential...
  4. ncbi request reprint Receptor adaptive responsiveness in disease models: 6-OHDA lesioned and spontaneously hypertensive rats
    C Caccia
    Research and Development, CNS Line, Farmitalia Carlo Erba, Nerviano, Italy
    J Recept Res 8:97-105. 1988
    ..S-1 receptors too are up-regulated in SHR. We must notice that though receptor hypersensitivity in the 6-OHDA model is linked to massive decreases in neurotransmitter levels, this mechanism seems not to exist in the SHR model...